Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan

Nakazawa T., Takahashi K., Kuwayama Y., Nomura A., Shimada F.

2022
Advances in Therapy

Therapeutic Area

Glaucoma
Categories

Post-Approval studies/RWE

Affiliations

Department of Ophthalmology, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan; Department of Ophthalmology, Kansai Medical University, 2-5-1 Shin-machi, Osaka, Hirakata, 573-1010, Japan; Fukushima Eye Clinic, 5-6-16, Fukushima, Fukushima-ku, Osaka, 553-0003, Japan; Santen Pharmaceutical Co., Ltd, 4-20, Ofukacho, Kita-ku, Osaka, 530-8552, Japan

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications